Lantern Pharma (LTRN) Receives a Buy from Colliers Securities

Colliers Securities analyst Kyle Bauser reiterated a Buy rating on Lantern Pharma (LTRNResearch Report) today and set a price target of $29.00. The company’s shares closed last Thursday at $12.97.

According to, Bauser is a 4-star analyst with an average return of 13.7% and a 57.8% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Chembio Diagnostics, Semler Scientific, and Motus Gi Holdings.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lantern Pharma with a $29.00 average price target.

See today’s analyst top recommended stocks >>

Based on Lantern Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $2.45 million. In comparison, last year the company had a GAAP net loss of $477.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm’s pipeline of development programs involves three small molecule drug candidates namely LP-100, LP-184, and LP-300.